Sarcoma News Survivors of pediatric cancer have a higher rate of clonal hematopoiesis than their peers at any age, a study suggests.
The location of KIT mutations is associated with response to ripretinib and sunitinib in patients with previously treated GIST, research suggests.
Larotrectinib prolongs survival when compared with non-TRK inhibitor standard care in adults with TRK fusion-positive cancers, a study suggests.
Adding ganitumab to standard chemotherapy does not provide a benefit for patients with metastatic Ewing sarcoma, a phase 3 trial suggests.
The risk of early death in AYAs with cancer depends on the type of malignancy they have as well as multiple demographic factors, a study suggests.
The approval was based on data from a phase 2 study that included 49 patients with unresectable or metastatic ASPS.
The incidence of Kaposi sarcoma is increasing among Black men and decreasing among White men in the United States, a study suggests.
None of the patients had grade 3 or higher acute radiation toxicity.
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
There are several factors that may increase the risk of thoracic soft tissue sarcoma in patients with a history of breast cancer.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
The incidence of invasive breast cancer among childhood cancer survivors decreased from the 1970s to the 1990s.
Phase 3 data do not support adding ifosfamide to adjuvant methotrexate, doxorubicin, and cisplatin in patients with high-grade osteosarcoma.
Researchers sought to increase the rate of serious illness conversations between clinicians and patients with cancer.
The approvals were based on data from the LIBRETTO-001 trial.
Cabazitaxel demonstrated antitumor activity in patients with previously treated, advanced dedifferentiated liposarcoma in a phase 2 trial.
Cancer patients with HIV do not receive curative or palliative care in the same way as their HIV-negative peers.
Adding trabectedin to doxorubicin doubled the median progression-free survival.
Dinutuximab plus GM-CSF produced a low disease control rate that did not meet a historical benchmark.
There was no significant difference in overall survival between patients who received actinomycin-D and those who received carboplatin.
Load More